Immunotherapy before lung cancer surgery shows promise in early trial

NCT ID NCT02818920

Completed Disease control Sponsor: Neal Ready MD PhD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the immunotherapy drug pembrolizumab in 35 people with early-stage non-small cell lung cancer. Participants received the drug before and after surgery to see if it could help the immune system attack cancer cells. The main goal was to check if surgery could still be done safely after the drug. Results help guide future research, but this treatment is not yet a standard option.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON SMALL CELL LUNG CARCINOMA

Contacts and locations

Show contact details

Locations

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, 03756, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States